Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2020 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the William Blair BioTech Conference

PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus...
July 28, 2020 16:44 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa

The randomized, double-blind GEM-3 trial will compare repeat dosing of either B-VEC or placebo in approximately 30 dystrophic epidermolysis bullosa (DEB) patients Top line data and BLA filing are...
July 20, 2020 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business Development

PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector...
June 08, 2020 16:01 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast

PITTSBURGH, June 08, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative medicines to treat diseases caused by...
May 18, 2020 21:57 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused...
May 18, 2020 16:15 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Proposed Public Offering of Common Stock

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused...
May 14, 2020 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)

KB105 was well tolerated with no adverse events or immune response following redosing Clearly detectable TGM-1 expression in all treated areas following initial and repeat administration....
May 04, 2020 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports First Quarter 2020 Financial Results and Provides Update on Operational Progress

KB105 interim Phase 1/2 clinical data for treatment of autosomal recessive congenital ichthyosis (ARCI) to be announced at the Society for Investigative Dermatology (SID) Annual Meeting in May 2020 ...
March 10, 2020 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports 2019 Financial Results and Business Progress

Phase 3 trial of B-VEC (Beremagene Geperpavec, previously “KB103”) to treat dystrophic epidermolysis bullosa (“DEB”) to start in 1H 2020 Interim results on Phase 1/2 clinical study on KB105 to...
February 25, 2020 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Change in Financial Leadership

PITTSBURGH, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...